Here’s Greenlight Capital’s Update on Coya Therapeutics (COYA)

Core Insights - Greenlight Capital's funds returned -3.6% in Q3 2025, underperforming the S&P 500's 8.1% return, and YTD returns were 0.4% compared to the index's 14.8% [1] Company Overview - Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company focused on developing treatments for ALS, with its lead drug recently entering clinical trials [3] - As of October 27, 2025, Coya Therapeutics' stock closed at $6.47 per share, with a market capitalization of $108.325 million [2] Investment Position - Greenlight Capital holds a small position in Coya Therapeutics, being the largest shareholder, due to its market capitalization of approximately $100 million [3] - Coya Therapeutics has shown a one-month return of 14.31%, but its shares have decreased by 36.51% over the past 52 weeks [2] Market Sentiment - Coya Therapeutics is not among the top 30 most popular stocks among hedge funds, with only 5 hedge fund portfolios holding the stock at the end of Q2 2025 [4] - While acknowledging Coya's potential, the company believes that certain AI stocks present greater upside potential and lower downside risk [4]